Cargando…

WCN23-0291 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBs) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS

Detalles Bibliográficos
Autores principales:	Qin, X., Yang, C., Cuixia, X., Zeng, J., Lin, X., Qiu, J., Liu, X., Lu, F., Bao, K., Johnson, D.W., Lundborg, C.S., Nitsch, D., Su, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2023
Materias:	Covid-19 and CKD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025661/ http://dx.doi.org/10.1016/j.ekir.2023.02.1002

Ejemplares similares

WCN23-1183 DISPARITIES IN CHRONIC KIDNEY DISEASE RISKS: DATA FROM THE CURE-CKD COVID-19 REGISTRY
por: Nicholas, S., et al.
Publicado: (2023)

WCN23-0981 RISK FACTORS FOR COVID-19 MORTALITY IN HEMODIALYSIS PATIENTS
por: TOMANOSKI, V., et al.
Publicado: (2023)

WCN23-0430 PREDICTORS FOR FAILURE REDUCTION OF HEMODIALYSIS FREQUENCY DURING THE PANDEMIC
por: Pattharanitima, P., et al.
Publicado: (2023)

WCN23-0345 EFFECTIVENESS OF COVID-19 VACCINE IN PATIENT UNDERGOING HEMODIALYSIS
por: FATIMAH, S., et al.
Publicado: (2023)

WCN23-0651 LONG-TERM EFFECTIVENESS OF COVID-19 VACCINE AMONG DIALYSIS PATIENTS
por: Rosa Diez, G., et al.
Publicado: (2023)

WCN23-0089 SERUM INDOXYL SULFATE IS ASSOCIATED WITH COVID-19 INFECTION AND DISEASE SEVERITY IN HEMODIALYSIS PATIENTS
por: Stepanova MD, N., et al.
Publicado: (2023)

WCN23-0825 TELENEPHROLOGY: MANAGING CHRONIC KIDNEY DISEASE DURING COVID-19 PANDEMIC
por: Sharma, S.K., et al.
Publicado: (2023)

WCN23-1238 COMORBIDITIES ASSOCIATED WITH INCREASED RISK OF DEATH IN CKD PATIENTS WITH COVID-19
por: BRAZ, B., et al.
Publicado: (2023)

WCN23-0938 IMPACT OF THE COVID-19 PANDEMIC IN PATIENTS ATTENDING RENAL CLINIC AT KINGSTON PUBLIC HOSPITAL, JAMAICA
por: DEWAR, D., et al.
Publicado: (2023)

WCN23-0616 SARS-COV-2 INFECTION AMONG HOSPITALIZED PATIENTS WITH CHRONIC KIDNEY DISEASE
por: Munaa, B., et al.
Publicado: (2023)

WCN23-0655 INCIDENCE AND OUTCOMES OF COVID-19 IN DIALYSIS PATIENTS. DATA FROM THE ARGENTINE REGISTRY OF CHRONIC DIALYSIS
por: Bisigniano, L., et al.
Publicado: (2023)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

WCN23-0389 ASSOCIATED FACTORS TO CLINICAL OUTCOMES OF COVID-19 AMONG HOSPITALIZED PATIENTS UNDERGOING MAINTENANCE DIALYSIS
por: MEDRIANO, R., et al.
Publicado: (2023)

WCN23-0519 VACCINE RESPONSE AGAINST SARS-Cov-2 AMONG HEMODIALYSIS PATIENTS IN TWO SENEGALESE CENTERS IN 2021
por: MOTOULA LATOU, L.N.P., et al.
Publicado: (2023)

WCN23-0787 A CASE OF IGA VASCULITIS THAT DEVELOPED GROSS HEMATURIA AND LOWER-LIMB PURPURA FOLLOWING COVID-19 VACCINES
por: MORI, K., et al.
Publicado: (2023)

WCN23-1086 ACUTE KIDNEY INJURY AFTER COVID 19 INFECTION IN CHRONIC KIDNEY DISEASE PATIENTS OF BANGLADESH: RETROSPECTIVE STUDY
por: NOBI, F., et al.
Publicado: (2023)

WCN23-0120 MEDIUM AND LONG TERM ANTIBODY RESPONSE TO COVID-19 VACCINATION IN PATIENTS RECEIVING HEMODIALYSIS (HD) - A CROSS SECTIONAL STUDY
por: Cheema, S., et al.
Publicado: (2023)

WCN23-0886 CONTRIBUTION TO THE STUDY OF ADVERSE EVENTS FOLLOWING VACCINATION AGAINST COVID-19 IN CHRONIC HEMODIALYSIS PATIENTS IN SENEGAL: A REVIEW OF 367 CASES
por: SARR, I., et al.
Publicado: (2023)

WCN23-1019 CUMULATIVE INCIDENCE OF COVID-19 AND VACCINE PROFILES AMONG ASEAN PERITONEAL DIALYSIS POPULATIONS: A PRELIMINARY RESULT OF THE "InCoV-PD" STUDY GROUP
por: Mushahar, L., et al.
Publicado: (2023)

WCN23-0544 CLINICAL PROFILE, IMMUNOSUPPRESSIVE MANAGMENT AND OUTCOME IN ADULT RENAL ALLOGRAFT RECIPIENTS WITH COVID-19 INFECTION: A CASE SERIES FROM SINGLE CENTRE IN BANGLADESH
por: MAHJABIN, S., et al.
Publicado: (2023)

WCN23-0166 NEW ONSET RENAL REPLACEMENT THERAPY IS A PREDICTOR OF COVID-19 ADVERSE OUTCOME IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE DUE TO TYPE 2 DIABETES MELLITUS
por: KLOCHKOVA, N., et al.
Publicado: (2023)

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Komiyama, Maki, et al.
Publicado: (2020)

Angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin‐converting enzyme 2 in patients with cardiovascular disease
por: Lebek, Simon, et al.
Publicado: (2020)

WCN23-1093 First report of durability of antibody response in maintenance haemodialysis patients and kidney transplant recipients vaccinated with ChAdOx1 nCoV-19 vaccine: A prospective, multicentre, observational, study
por: CHAUHAN, S.
Publicado: (2023)

Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust
por: Bean, Daniel M., et al.
Publicado: (2020)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
por: Kim, Ju Hwan, et al.
Publicado: (2020)

Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey
por: Ibrahim, Sarai L., et al.
Publicado: (2016)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
por: Paranjpe, Rutugandha, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
por: Ong, Hean Teik, et al.
Publicado: (2013)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes
por: Wong, Chun-Ka, et al.
Publicado: (2022)

WCN23-0624 ACUTE KIDNEY INJURY AND COVID-19
por: JERNDAL, H., et al.
Publicado: (2023)

User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study: ACEI/ARB and vascular calcification
por: Takaori, Kaori, et al.
Publicado: (2021)

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
por: Bhandari, Sunil, et al.
Publicado: (2016)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5rtuhc8gsvfmoo0btq3jekklal